SG Americas Securities LLC Has $1.17 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

SG Americas Securities LLC raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 56.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 35,097 shares of the company’s stock after purchasing an additional 12,599 shares during the period. SG Americas Securities LLC owned approximately 0.06% of Harmony Biosciences worth $1,165,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of Harmony Biosciences by 6.5% in the 1st quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 50,800 shares of the company’s stock valued at $1,685,000 after buying an additional 3,100 shares in the last quarter. GAMMA Investing LLC raised its stake in Harmony Biosciences by 222.9% during the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company’s stock worth $97,000 after buying an additional 2,022 shares during the period. Bridge City Capital LLC lifted its holdings in Harmony Biosciences by 54.8% during the first quarter. Bridge City Capital LLC now owns 160,739 shares of the company’s stock worth $5,335,000 after acquiring an additional 56,930 shares in the last quarter. First Citizens Bank & Trust Co. acquired a new position in Harmony Biosciences in the first quarter valued at about $216,000. Finally, Financial Management Professionals Inc. acquired a new position in Harmony Biosciences in the first quarter valued at about $29,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Price Performance

Shares of HRMY opened at $32.47 on Wednesday. The company has a 50 day moving average of $32.40 and a 200-day moving average of $34.03. The company has a quick ratio of 3.63, a current ratio of 3.67 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $1.86 billion, a P/E ratio of 12.39, a P/E/G ratio of 0.49 and a beta of 0.87. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 20.53% and a return on equity of 24.32%. The business had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same quarter last year, the firm earned $0.67 earnings per share. The firm’s revenue for the quarter was up 19.5% compared to the same quarter last year. As a group, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HRMY has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Mizuho increased their target price on Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a research note on Thursday, May 15th. UBS Group dropped their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Monday, April 28th. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a “strong-buy” rating in a report on Tuesday, May 13th. Finally, Oppenheimer began coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They set an “outperform” rating and a $61.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $53.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.